Is Catalent a Buy?
The world's pharma and biopharma companies are sprinting to develop hundreds of treatments for COVID-19 and vaccines for SARS-CoV-2. Almost half of those have been pitched to drug manufacturer Catalent (NYSE: CTLT), which helps customers to safely and efficiently produce small molecule and biologic drugs in volumes sufficient for clinical trials all the way up to commercial sales.
Investors have rewarded the company's position in the global value chain by pushing the stock to all-time highs. It helps that the contract development and manufacturing organization (CDMO) has inked deals to produce the potential SARS-CoV-2 vaccines from Arcturus Therapeutics and Johnson & Johnson. Although, to be fair, Catalent was on a promising trajectory before the health crisis began.
Given all of the moving parts, investors might be wondering if the momentum proves sustainable when the coronavirus pandemic runs its course. Is this growth stock a buy?
Source Fool.com
